Bevacizumab plus paclitaxel optimization study with interventional maintenance endocrine therapy in advanced or metastatic ER-positive HER2-negative breast cancer-BOOSTER trial, a multicenter randomized phase II study
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 May 2017
At a glance
- Drugs Bevacizumab (Primary) ; Hormones; Paclitaxel
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms BOOSTER
- Sponsors Chugai Pharmaceutical
- 10 Jun 2017 Biomarkers information updated
- 06 Mar 2017 Planned End Date changed from 30 Jun 2017 to 1 Jun 2019.
- 06 Mar 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.